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Seprase or Fibroblast activation protein (FAP) is an integral membrane serine 
peptidase, which has been shown to have gelatinase activity. Seprase has a dual 
function in tumour progression. The proteolytic activity of Seprase has been shown to 
promote cell invasiveness towards the ECM and also to support tumour growth and 
proliferation. Seprase appears to act as a proteolytically active 170-kDa dimer, 
consisting of two 97-kDa subunits. It is a member of the group type II integral serine 
proteases, which include dipeptidyl peptidase IV (DPPIV/CD26) and related type II 
trans-membrane prolyl serine peptidases, which exert their mechanisms of action on 
the cell surface. DPPIV and Seprase exhibit multiple functions due to their abilities to 
form complexes with each other and to interact with other membrane-associated 
molecules. Localization of these protease complexes at cell surface protrusions, called 
invadopodia, may have a prominent role in processing soluble factors and in the 
degradation of extracellular matrix components that are essential to the cellular 
migration and matrix invasion that occur during tumour invasion, metastasis and 
angiogenesis. 
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1. Introduction 
Wound healing and tumour development are dynamic progressive processes that 
involve the interaction of several tissue types and have many mechanistic similarities. 
The composition of tumour stroma markedly resembles that of wound granulation 
tissue, although a distinguishing feature of the tumour stroma is the absence of 
platelets and a lower density of inflammatory cells [1]. In cancer, these changes in the 
stroma drive invasion and metastasis, the hallmarks of malignancy (Fig. 1.). Tumour 
cells can produce many of the same growth factors that activate the adjacent stromal 
tissues as in wounding or fibrosis. Activated fibroblasts and infiltrating immune cells 
(macrophages) secrete proteases (MMPs) and cytokines such as Fibroblast Growth 
Factor-2 (FGF-2). These factors potentiate tumour growth, stimulate angiogenesis and 
induce fibroblasts to undergo differentiation into myofibroblasts and into smooth 
muscle [2]. 
 
Cell surface proteases play an important role in facilitating cell invasion into the 
extracellular matrix. Proteases associate at plasma membrane protrusions, called 
invadopodia, which contact and dissolve the matrix. Invadopodia degrade a variety of 
immobilised substrates including fibronectin, laminin and type I collagen [3]. Integral 
membrane proteases may contribute significantly to ECM degradation by metastatic 
cells by virtue of their localisation at invadopodia which are in contact with the ECM. 
Integral membrane proteases can be defined as a group of cell surface glycoproteins 
that contain extracellular domains of either metallo- or serine-proteases, a 
transmembrane domain and a short cytoplasmic tail. Examples of such 
transmembrane glycoproteins include meprin, matrix metalloproteinase, DPPIV, 
  - 4 - 
fibroblast activation protein α (FAPα) / Seprase and GBase. Abundant expression of 
these enzymes is associated with poor prognosis [4]. 
 
This review will take a detailed look at the serine protease Seprase (surface expressed 
protease) or Fibroblast Activation Protein α (FAPα), a 170kDa integral membrane 
gelatinase, which belongs to the S9b peptidase family [5, 6]. FAPα, formerly known 
as F19 Cell Surface Antigen, is an inducible cell surface glycoprotein that was 
originally identified in 1986 in cultured fibroblasts using the monoclonal antibody 
(mAb) F19 [7-9][7, 8]. In the early years using the mAb F19, malignant epithelial 
cancers such as breast, lung, colon and ovarian were found to be F19- . In 1994, the 
F19 Cell Surface Antigen was named Fibroblast Activation Protein α (FAPα) . In 
1990 a 170kDa gelatinase was identified in the human malignant melanoma cell line 
LOX . The 170kDa membrane-bound protease was found to be associated with the 
expression of invasiveness by human malignant melanoma cells. In 1994, the 170kDa 
gelatinase was named Seprase . Seprase was originally identified as a glycoprotein 
peptidase selectively expressed on the surface of invadopodia and was isolated from a 
human malignant melanoma cell line LOX [3, 12][9]. The expression of Seprase 
correlates with the invasiveness of human melanoma and carcinoma cells [12][9]. 
Using anti-Seprase mAbs, Seprase was seen to be expressed in stromal fibroblasts of 
more than 90% of all epithelial tumours including lung, colorectal and breast 
carcinomas (primary and metastatic) .  Molecular cloning of both FAPα and Seprase 
revealed that they are the same cell surface serine protease which is found on 
chromosome 2q23 [12-16][9-13]. The fact that FAPα and Seprase are the same 
protease means that the above immunohistochemistry results contradict each other. 
The reason for the differing results is due to the different monoclonal antibodies 
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recognising different parts of the serine protease. For the clarity of this review, the 
protease is referred to as Seprase throughout.  
 
2. Classification of Seprase / Fibroblast Activation Protein alpha (FAPα) 
Seprase (EC 3.4.21.B28) belongs to the small family of serine integral membrane 
peptidases (SIMPs). These peptidases are inducible, specific for proline-containing 
peptides and macromolecules and active on the cell surface [15]. Post proline 
peptidases modify bioactive peptides and change their cellular functions. This class of 
peptidases have important roles in cancer [14, 15, 17-19]. This group of enzymes also 
includes prolyl endopeptidase, dipeptidyl peptidase 8 and dipeptidyl peptidase IV-β 
[19]. However, the best studied of this class of enzymes is dipeptidyl peptidase IV 
(DPPIV or CD26) (EC 3.4.14.5) [19]. Studies have shown the importance of DPPIV 
in regulating tumour cell behaviour and function [20]. Seprase shows up to 52% 
homology to DPPIV, both being members of the S9b peptidase family [21]. Seprase 
is, therefore, a member of the DPPIV-like gene family [5] grouped in the subfamily 
S9b of the peptidase family S9 (prolyl oligopeptidase family), clan SC [6]. Even 
though all SIMP members are known to cleave prolyl peptide (Pro-Xaa) bonds there 
are conflicting reports on possible dipeptidyl peptidase activity associated with 
Seprase but its main distinguishing feature is its gelatinase activity [22, 23]. An early 
report had suggested that DPPIV had gelatinase activity [24]. However, more recent 
reports suggest otherwise [22, 23]. The exact nature of the physiological roles Seprase 
plays are only beginning to be understood but insights into potential functions of 
Seprase can be obtained from the vast amount of work done on DPPIV. 
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3. Structure and Biochemical Aspects 
Active Seprase is a 170kDa homodimer that contains two N-glycosylated 97kDa 
subunits. The 760 amino acid Seprase protein (GenBank GI 1888316) is a type II 
integral membrane protein with a large C-terminal extracellular domain. Seprase has 
been shown to shed from the cell surface and recent studies by our group have 
identified a serum form of the protease [25][22]. A second group has recently 
identified the soluble form of Antiplasmin Cleaving Enzyme (APCE) as Seprase 
[26][23].  
 
The Seprase monomer has 5 potential N-glycosylation sites, 13 cysteine residues, 3 
segments that correspond to highly conserved catalytic domains of serine proteases, a 
hydrophobic transmembrane segment and a short cytoplasmic tail (6 amino acids) 
(Fig. 1. ref [14][11]). The crystal structure of the extracellular domain of Seprase has 
recently been resolved (Fig. 2.) [27][24]. This has provided valuable information on 
the substrate specificity of Seprase (discussed further in this Section and also in 
Section 7.). 
 
Each subunit contains topologically distinct domains: the β-propeller (residues 54-
492) and the α/β-hydrolase domain (residues 27-53 and 493-760) (Fig. 2.). The 
catalytic triad is located at the interface of the β-propeller and the α/β-hydrolase 
domain. The arrangement of the catalytic triad in the order nucleophile-acid-base is a 
characteristic of the α/β hydrolase domain [28][25]. This domain features mostly 
parallel β-sheets connected by α-helices on either surface of the sheet (Fig. 3A.). The 
sheets are twisted and radially arranged around their ventral tunnel. The eight bladed 
β-propeller domain is situated on top of the catalytic triad and may serve as a ‘gate’ to 
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selectively filter protein access to the catalytic triad (Fig. 3B.) [27, 29][24, 26]. The β-
propeller domain in Prolyl Oligopeptidase has been shown to regulate proteolysis 
[30][27]. The oscillating propeller blades have been shown to act as a gating filter 
during catalysis, letting small peptide substrates into the active site while excluding 
large proteins to prevent accidental proteolysis in the cytosol. The active site is 
accessible in two ways; (i) through a cavity formed between the β-propeller and (ii) 
through the hydrolase domain. The side opening has a diameter of ~24Å in contrast to 
the narrower β-propeller opening (~14Å).  
 
As mentioned earlier, DPPIV shows similar structure homology to Seprase. In 
DPPIV, the N-terminal hydrophobic sequence represents an uncleavable signal 
peptide, that also functions as a membrane-anchoring domain [6, 31][6, 28]. In 
Seprase, the N-terminal domain possibly has a similar role as a signal peptide, 
although there is no published data to support this. A highly conserved residue Asp599 
in DPPIV has been shown to be important in enzyme processing such as proper 
folding, dimerisation and transport [15][12]. A mutation in this residue (D599A) 
specifically decreased the cell surface expression of DPPIV in stably transfected 
mouse fibroblasts. Seprase also has this conserved Asp599 residue (Fig. 4.); therefore, 
it is possible to conclude that this residue is also important in the processing of the 
Seprase enzyme.  
 
The Seprase gene has been observed in several species (Fig. 4.). A mouse homologue 
has been identified [32][29] as well as a Xenopus laevis homologue [33][30]. The 
mouse Seprase gene spans approximately 60kb and contains 26 exons ranging in size 
from 46bp to 195bp. This genomic organisation is similar to that of the human 
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Seprase gene [32]. The catalytic serine residue arranged within the consensus 
sequence G-X-S-X-G is split between two exons. Gly-Trp is located at the very end of 
exon 21 and Ser-Tyr-Gly at the beginning of exon 22 (discussed further in Section 
3.1.). This arrangement differs from the typical serine protease where the complete 
serine consensus site is encoded within one exon. The study of the mouse homologue 
has shown alternative splicing and 3 distinct Seprase splice variants have been 
detected in tissues [34][31]. An alternative spliced Seprase was later identified in the 
human melanoma cell line LOX which encodes a novel truncated isoform [35][32]. 
The splice variant encodes for a 239 amino acid polypeptide with a molecular weight 
of 27kDa that precisely overlaps the carboxyl-terminal catalytic region of the wild 
type Seprase. An alignment of eukaryotic Seprase C-terminal amino acid sequences is 
shown in Fig. 4. Sequence homology is represented in grey scale shading, with black 
being the highest homology. This figure also illustrates that the C-terminal catalytic 
region of Seprase is highly homologous throughout the different species.  
 
The charged N-terminal end of substrate peptides is recognised by two glutamates 
(Glu motif). Comparison of the crystal structure of Seprase and DPPIV revealed one 
major difference in the vicinity of the Glu motif (Glu203 – Glu204 for Seprase; Glu205 – 
Glu206 for DPPIV) within the active site of the enzyme (Fig. 2. ref [27][24]). The 
importance of the Glu motif in DPPIV catalysis has been confirmed by single-point 
mutations that abolish the enzymes aminopeptidase activity [36][33]. Detailed 
comparison of Seprase and DPPIV revealed that the Ala657 residue in Seprase, instead 
of Asp663 as in DPPIV, reduces the acidity in this pocket. This change could explain 
the lower affinity for N-terminal amines by Seprase [27][24]. Mutant proteins were 
developed to determine the importance of these two residues. Studies have shown that 
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in DPPIV, the replacement of Asp663 by an alanine Ala663 results in a ~4-fold decrease 
in catalytic efficiency for N-terminal dipeptides, with a concomitant increase in 
efficiency to cleave Z-Gly-Pro-AMC (which has been shown to be cleaved by 
DPPIV). This mutation caused the wild type DPPIV catalytic efficiency for Z-Gly-
Pro-AMC to be increased from 9 M-1s-1 to 1.6 M-1s-1. 
  
Structural composition of the active sites of Seprase and DPPIV revealed similar S2-
S2’ specificity pockets. The S1’ subsite (numbered according to [37][34]) in Seprase is 
flat and could accommodate most amino acids. The S2’ active site pocket is lined by 
Trp623 and Tyr745. These residues would be expected to interact with large aliphatic 
side chains of peptide substrates. The S1 specificity pocket in Seprase is a well defined 
hydrophobic pocket lined by Tyr625, Val650, Trp653, Tyr656, Tyr660 and Val705. This site 
optimally accommodates a proline residue. Large hydrophobic and aromatic residues 
can be modelled in the hydrophobic S2 pocket, defined by residues Arg123, Phe350, 
Phe351, Tyr541, Pro544, Tyr625 and Tyr660 [27][24].  
 
3.1. Catalytic Classification 
In its membrane form, the majority of Seprase including its catalytic domain is 
exposed to the extracellular environment (Fig. 1. ref [14][11]). The catalytic domain 
consists of the catalytic serine (S624) flanked by glycines in the classical consensus 
sequence for an active site serine, G-X-S-X-G. This conserved serine protease motif is 
present as G-W-S-Y-G. The catalytic serine in conjunction with Asp702 and His734 
comprises the catalytic triad [12, 16, 21][9, 13, 18]. The orientation of these residues 
is similar to members of the prolyl oligopeptidase family and its structural 
organisation is similar to that of DPPIV. Therefore, this enzyme is classified as a non-
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classical serine protease. An interesting observation made in DPPIV is that a single 
substitution of either Gly residue in the motif resulted in the retention of the newly 
synthesised enzyme in the endoplasmic reticulum and rapid degradation [6]. This 
suggests that both residues are also essential for correct folding of the enzyme and 
transport to the cell surface. The histidine acts as a general acid-base catalyst 
activating the nucleophilic group, the hydroxyl group of the serine acts as a 
nucleophile in the attack on the peptide bond while the aspartic acid stabilises charged 
tetrahedral intermediates formed in the reaction [38, 39][35, 36].  
 
3.2. Biochemical Properties of Seprase 
Post translational modifications of the Seprase protein such as N-glycosylation occurs 
and it is thought that the N-terminus may be blocked [12]. The resolved crystal 
structure of Seprase shows that there are 5 potential glycosylation sites on the 
asparagine residues 49, 92, 227, 314 and 679. Four are located in the β-propeller 
domain and one is located in the hydrolase domain [27]. The glycosylated form of 
Seprase has both post-prolyl dipeptidyl peptidase and gelatinase activities while the 
non-glycosylated form lacks any detectable activity [40][37].  
 
Reports show that the gelatinase activity of Seprase was completely blocked by 
serine-protease inhibitors, including DFP and PMSF [11, 25][22, 38]. Seprase could 
be affinity labelled by [3H]-DFP, but the proteolytically inactive 97kDa subunit could 
not [12][9]. This confirmed the existence of a serine protease active site on the 
dimeric form of the enzyme. This was further demonstrated by the loss of proteolytic 
activity upon the dissociation of its 97kDa subunits following treatment with acid, 
heat, or cysteine and histidine modifying agents [12][9]. Therefore, it may be 
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concluded from this that Seprase activity is determined by the association of its 
subunits to form a proteolytically active dimer [27][24]. The proteolytic gelatinase 
activity of membrane bound Seprase was found to be maximal at neutral pH and was 
enhanced by a mixture of 2mM EDTA and 2mM DTT (which inhibits metal-
dependent proteases and activates cysteine proteases respectively) [11][38]. However, 
a previous study of the soluble form of Seprase demonstrated that EDTA had no 
effect on the proteolytic dipeptidyl peptidase activity and, contrary to previous reports 
DTT had a detrimental effect, with 5mM DTT causing a 10% loss of activity [41][39].  
 
A more recent study using a generated soluble recombinant Seprase (r-Seprase, 160-
kDa), lacking cytoplasmic and transmembrane domains, found that in the presence of 
putative EDTA sensitive activators, r-Seprase was converted into 70-kDa to 50 kDa 
shortened forms of Seprase (s-Seprase) [42][40]. These shortened forms of Seprase 
exhibited a 7-fold increase in gelatinase activity, whereas levels of DPP activity 
remained unchanged [42][40]. Data shows that proteolytic truncation of the NH2-
terminal peptides of Seprase reduces steric hindrance for the gelatin substrate but not 
the dipeptidyl peptidase substrate, thereby increasing the gelatinolytic activity of 
Seprase [42][40]. Table 1 summarises some of the biochemical properties of Seprase. 
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4. Purification and Activity Detection of Seprase 
Seprase has been purified from cell membranes and shed vesicles of LOX human 
amelanotic melanoma cells [3, 11][3, 38]. It has also been purified from 9-day old 
chicken embryos [43][41]. Size exclusion chromatography (S-200) and affinity 
chromatography using wheat germ agglutinin (WGA)-agarose are two of the most 
widely used resins for Seprase purification [11, 12][9, 38]. Immunoaffinity 
purification of Seprase has also been utilised, with the mAb F19 pre-coated onto 
Sepharose CL-4B beads [10][42]. Soluble forms and isoforms of these membrane 
proteases are beginning to be found in biological fluids [15, 25][12, 22]. Recently our 
group have published the purification scheme for the soluble form of Seprase from 
bovine serum [25][22]. This purification procedure involved a combination of 
hydrophobic interaction chromatography, hydroxylapatite, and cibacron blue 
chromatography followed by size exclusion chromatography.  
 
Until recently, the most sensitive assay available for Seprase detection involved 
gelatin zymography, which exploits the established gelatinase activity associated with 
Seprase [12][9]. However, this is not a quantitative assay. A semi-quantitative assay 
was developed based on the degradation of radiolabelled gelatin substrate and 
subsequent qualitative measurement of the released fragments [43][41]. Seprase was 
reported to possess prolyl dipeptidyl peptidase activity [15, 32, 40, 44][12, 29, 37, 43] 
and Ala-Pro-AFC was seen as a potential sensitive fluorogenic substrate. 
Interestingly, conflicting results exist with reports that Seprase has no such prolyl 
dipeptidyl peptidase cleavage activity [12, 45][9, 44].  
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5. Tissue Distribution of Seprase 
Studies have shown that Seprase is transiently expressed in certain normal fetal 
mesenchymal tissues, during wound healing and in reactive stroma responding to 
epithelial cancers and some sarcomas [7, 8]. Normal adult tissues as well as malignant 
epithelial, neural and haematopoietic cells are generally Seprase-negative. The initial 
identification of Seprase involved the study of six surface glycoproteins that were 
differentially expressed during normal development, proliferative activation and 
malignant transformation of mesenchymal cells and tissues [46][45]. The monoclonal 
antibody F19 was used to define the human cell-surface glycoprotein Seprase. The 
F19 antigen (now known as Seprase) was found to be expressed on cultured 
fibroblasts derived from various organs, several foetal mesenchymal tissues, scar 
tissue and a proportion of sarcoma cell lines. In normal adult tissues expression of the 
F19 antigen was restricted to occasional fibroblasts and to a set of pancreatic islet 
cells. The pattern observed in this initial study suggests that Seprase is a cell-surface 
marker for proliferating mesenchymal cells and that its expression may be induced by 
normal growth factors or during malignant transformation [46][45].  
 
Another early study describes the induction of F19 in the reactive mesenchyme of 
epithelial tumours (carcinomas) [7]. Fibroblasts positive for the F19 antigen (Seprase) 
using immunohistochemical studies were found in primary and metastatic carcinomas 
including colorectal, breast, ovarian, bladder, and lung carcinomas. This study also 
analysed dermal incision wounds and found that F19 was strongly induced during scar 
formation. These studies suggest that the F19+ phenotype correlates with specialised 
fibroblast functions in wound healing, inflammation and malignant tumour growth 
[7]. Another important observation from this study is that the cellular immunostaining 
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patterns obtained with the tumour tissue suggests that Seprase is localised exclusively 
in the cell membrane/cytoplasm of fibroblastic cells. This cellular staining is 
consistent with the cell surface localisation of Seprase in cultured fibroblasts [7]. 
 
Since these early reports, more studies have shown that Seprase is expressed in 
reactive human stromal fibroblasts [23][20]. Studies have confirmed the expression of 
Seprase in primary breast infiltrating ductal carcinoma, colon adenocarcinoma and 
lung adenocarcinoma and also in metastatic colon adenocarcinoma in the hepatic 
system [23, 47]. Several groups have shown Seprase to be expressed in the reactive 
stromal fibroblasts of human breast cancer and its absence in normal breast tissue [7, 
10, 16, 48]. As mentioned above, Seprase is expressed by infiltrating ductal 
carcinoma (IDC) cells in breast cancer patients; however it is not expressed by normal 
breast epithelia [23, 47, 49]. Further work has shown that Seprase expression is not 
confined to stromal fibroblasts but that the protease is also expressed in some types of 
malignant cells of epithelial origin [4, 15, 50-52]. Stromal expression of Seprase in 
IDC of the breast was associated with longer survival of patients [48]. Contrary to 
this, a recent study of patients with epithelial ovarian carcinoma has shown that the 
overall survival decreased with expression of Seprase protein (p = 0.03) [52]. This 
report suggests that the conflicting data may result from the previous studies having 
either small samples and series or short follow-up period [52]. Reports differ in the 
cellular localisation of FAPα and Seprase depicted by immunochemistry [15, 49]. The 
apparent difference is thought to be partially due to the use of antibodies that 
recognise, with varying affinity, different epitopes exhibited by FAPα (derived from 
activated fibroblasts) and Seprase (derived from invasive cancer cells).  
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Expression patterns of Seprase were examined in cervical carcinoma and cervical 
intraepithelial neoplasm [50]. This embraces both carcinoma in situ and the precursor 
lesions known as dysplasia or ‘disordered differentiation’. Some micro-invasive 
carcinomas and all invasive carcinomas showed Seprase immunoreactivity in the 
cancer cells [50]. The findings in this study show a direct correlation between 
gelatinase expression and the malignant phenotype. Thus Seprase may be an early 
marker of tumour progression characterising Seprase expression with invasive 
growth. A separate study to support the concept was performed by Iwasa [4], whom 
examined Seprase expression in colorectal cancer specimens. Immunoblotting showed 
higher levels of Seprase protein in the cancer tissue than in normal colorectal tissue (p 
< 0.001). The results also revealed a significant correlation between Seprase 
expression and lymph node metastasis (p = 0.033).  
 
Expression patterns of Seprase in human gastric cancer were investigated using 
immunohistochemistry and the study showed that there were distinct differences in its 
expression between intestinal- and diffuse-type gastric cancer [51]. Results also 
showed, as in Iwasa [4], a correlation between Seprase expression and depth of 
invasion. In intestinal cancer, the stromal expression of Seprase significantly 
correlated with liver metastasis (p = 0.0002) and lymph node metastasis (p < 0.0001). 
In contrast, in diffuse-type cancer there was no correlation between stromal Seprase 
expression and lymph node metastasis (p = 0.0821) [51]. A separate study looked at 
the expression of Seprase at the mRNA and protein level. This study found that 
Seprase expressing carcinoma tissues were more prominently found in the scirrhous 
type than in other types of gastric carcinoma [53].  
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Immunohistochemical studies have shown Seprase expression was induced in patients 
with idiopathic pulmonary fibrosis (IPF) [54]. Its expression pattern is restricted to 
fibroblasts in areas of ongoing tissue injury (Fig. 3. ref [54]). Seprase was recently 
identified for the first time on chondrocyte membranes under conditions that 
promoted cartilage resorption and elevated expression in cartilage from osteoarthritis 
(OA) patients [55]. The results from this study supported a role for Seprase in the 
mechanisms leading to cartilage degeneration in OA. Gene expression profiling in the 
murine model showed a 7-fold increase in Seprase expression in inflamed, compared 
to non-inflamed paws [56]. 
 
A study by Huber [57] found that Seprase was expressed in benign and malignant 
melanocytic skin tumours. This is in contrast to the findings in benign epithelial 
tumours, in which little or no expression of Seprase was observed on stromal 
fibroblasts [7, 47]. Normal adult skin, however, did not have any detectable Seprase 
activity. These contradictory results could be explained if melanocytic naevi (moles) 
are considered as precursor lesions for melanoma development, characterised by 
constitutively-active tumour stroma [57, 58]. Gene expression studies have identified 
Seprase to be uniquely overexpressed in aggressive fibromatosis [59]. Aggressive 
fibromatosis is locally invasive but rarely metastasises. There are histologic 
similarities between this disease and the proliferative phase of wound healing. 
 
To further support the concept that Seprase is expressed during wound healing, 
studies have shown that stellate cells at the tissue remodelling interface of cirrhosis in 
humans, express Seprase [60, 61]. Hepatic stellate cells (HSCs) are a known major 
source of ECM degrading enzymes and protease inhibitors of hepatic tissue 
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remodelling [62]. It is thought that Seprase may contribute to the (HSC)-induced 
ECM changes of cirrhosis. Seprase expression was also detected in the hepatic 
parenchyma of patients with chronic hepatitis C virus (HCV) infection. In fact, 
Seprase expression correlates with the degree of fibrosis in HCV (p < 0.0001) [63]. 
This adds considerable weight to the assertion that Seprase has a role in the 
pathogenesis of chronic liver disease.  
 
Another study involving the Xenopus laevis Seprase homologue describes the 
enzymes increased expression during hormone-induced tail resorption, indicating a 
possible role in tissue remodelling [33]. An extension of this concept is that Seprase 
has been found to be expressed during mouse embryo development [64]. However, 
Seprase-deficient mice showed no overt developmental defects and were viable. In 
order to analyse Seprase expression at various stages of embryonic development, mice 
deficient in Seprase but expressing β-galactosidase under the control of the Seprase 
promoter were developed (Seprase -/- lacZ). These Seprase-/- lacZ mice expressed β-
galactosidase at regions of active tissue remodelling during embryogenesis supporting 
a role for Seprase in tissue remodelling processes [64].  
 
Overall, Seprase has been seen to be expressed in stromal fibroblasts of more than 
90% of all epithelial tumours including lung, colorectal and breast carcinomas 
(primary and metastatic) [7]. It has also been shown to be expressed in post-natal non-
tumour tissues [15], in a proportion of bone and soft tissue sarcoma tumour cells [47], 
in granulation tissue of healing wounds [7], and on pancreatic cells [46]. However, 
normal adult tissue, benign and premalignant epithelial lesions are generally Seprase 
negative. Seprase-positive cells were found in close proximity to the endothelial cells 
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of the tumour capillaries and surround the tumour nodules [7, 46, 65]. These suggest 
that Seprase may have a critical role to play in altering the microenvironment to 
promote tumour growth, thus enhancing the theory that metastatic effects may depend 
on proteolytic enzymes derived not only from tumour cells but also from stromal 
cells.  
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6. Physiological and Pathological Roles for Seprase 
High levels of Seprase activity have been positively correlated with the invasive 
behaviour of many malignantly transformed cells but its function in malignancy is 
still unknown [3, 11, 66]. There is evidence that Seprase could act as both a tumour 
suppressor and tumour promoter. Sections 6.1 and 6.2 put the case forward for both 
situations.  
 
6.1. Tumour Suppression 
There is growing evidence that Seprase may play a role as a tumour suppressor [67-
69]. Initial studies have shown the loss of DPPIV expression as normal melanocytes 
progress to malignant melanoma [69]. Experiments have shown that the re-expression 
of DPPIV was able to change the mouse melanoma cells to a more differentiated and 
normal phenotype with a return to dependence on exogenous growth factors [69]. 
Wesley [69] observed that the re-establishment of dependence on exogenous growth 
factors occurred even when a catalytically inactive mutant of DPPIV was expressed. 
This group accredited this to the expression of endogenous Seprase which was co-
induced when the mutant DPPIV was expressed. More recent studies have provided 
direct evidence in the case for Seprase as a tumour suppressor. It was observed that 
the expression of Seprase decreased the tumourigenicity of mouse melanoma cells in 
animals and restored contact inhibition and growth factor dependence [67]. Another 
interesting result from this study is that the catalytic mutant of Seprase contributed to 
the tumour suppression in the absence of active protease activity. In addition to this, 
the study demonstrated that while DPPIV expression induced Seprase expression, the 
converse was not so; i.e. Seprase expression did not induce DPPIV expression. 
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Therefore, it was concluded that the tumour-suppressive activities of wild-type and 
mutant Seprase are most likely due to the inherent abilities of Seprase.  
 
6.2. Tumour Progression 
The role of Seprase in breast cancer has been investigated using human breast cancer 
cell lines that normally express Seprase (MDA-MB-435 and MDA-MB-436) [70]. 
Anti-sense suppression of Seprase rendered these cells sensitive to serum starvation 
while control transfectants with high levels of Seprase expression grew well in the 
absence of serum [70]. Goodman [70] concluded that the breast cancer cells with high 
levels of Seprase expression are less dependent on exogenous serum factors for 
growth and have gained independence from normal growth regulatory controls. 
Independence from normal growth regulation is a key characteristic of malignancy 
transformed cells that distinguishes them from normal cells [71]. 
 
Seprase expression was also engineered in the human breast cancer cell line MDA-
MB-231, which lacks normal Seprase expression [72]. A mouse model was utilised to 
demonstrate that Seprase-expressing tumours grew more rapidly and were highly 
vascular when compared to tumours of control transfectants which lacked Seprase 
expression [72]. This group did find that when these cells were grown in vitro, cells 
that did express Seprase grew at the same rate as those that did not. This indicated that 
Seprase had a more noticeable effect on tumour cell growth in the mouse mammary 
fat pad environment. For tumours to grow and integrate into the surrounding normal 
tissue, they must attract a blood supply (angiogenesis), which sustains growth. This 
study was the first evidence for a pro-angiogenic function for Seprase and it can be 
concluded that Seprase expression promotes growth of breast cancer tumours at least 
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in part by driving angiogenesis [72]. This conclusion is supported by studies showing 
that Seprase mRNA is up-regulated by endothelial cells undergoing re-organisation 
and capillary morphogenesis [73]. Both these findings together suggest that Seprase 
expression by breast cancer cells favourably alters the tumour microenvironment.  
 
Further evidence of these growth-promoting effects of Seprase have been described 
[29, 74]. Murine Seprase was transfected into HEK293 human embryonic kidney 
cells. It was then shown that the tumours derived from these Seprase expressing cells 
grew more rapidly than the control transfectants. This group also demonstrated in an 
animal model, that antibodies found to inhibit the dipeptidase activity of Seprase, also 
suppressed the growth of tumours which were derived from cells expressing Seprase 
[29]. Wang and co-workers [75] found that the over-expression of Seprase in the 
human hepatic stellate cell (HSC) cell line LX-2 increased cell adhesion, migration 
and invasion. Interestingly, this group found that Seprase proteolytic activity was not 
necessary for these functions. These findings further support a pro-fibrogenic role for 
Seprase by indicating that, in addition to its enzymatic functions, Seprase has 
important non-enzymatic functions [75]. Overall, it can be concluded from these 
studies that Seprase activity mediates in some way the increased tumour growth. 
Recently increased DPPIV expression and enzymatic activity has been shown to be 
associated with tumour grade severity in human astrocytic tumours [76]. There is no 
evidence to date that Seprase dipeptidyl peptidase activity can be correlated with 
tumour grade. 
 
In summary there is an obvious discrepancy between Seprase function in tumour 
promotion and tumour suppression. It is proposed by some researchers that Seprase 
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expression has a profound effect on cells that do not normally express Seprase and 
that the context in which Seprase is expressed determines the biological response to 
Seprase (either promotion or inhibition of growth) [77]. This group has created a 
model that explains all the reported findings so far. It describes how Seprase 
associates with membrane-bound signalling molecules causing transmission of growth 
stimulatory or inhibitory signals (Fig. 2. ref [77] for an example of stimulatory 
signals). The factor that determines this must reside in the signalling molecules that 
are available for interaction with Seprase on the cells. Therefore it was concluded that 
Seprase carries out its biological functions in a cell-context dependent manner through 
a combination of its protease activity and its ability to form complexes with other cell 
surface molecules [77].  
 
 
6.3. Seprase complexes in cellular invasiveness 
Seprase associates with α3β1 integrin, DPPIV, MMP-2, membrane-type 1 MMP and 
uPA at the invadopodia of human malignant cells and so may interact with these 
proteinases and receptors and with associated cascades [3, 55, 78, 79].  
 
The integrin family of transmembrane adhesion proteins have been shown to exhibit 
multiple functions, including adhesion to ECM and their localisation at invadopodia 
[79]. One theory is that integrins are involved in recruiting proteases to these sites of 
cell invasion. The α3β1 integrin has been shown to associate with Seprase and it is 
thought that α3β1 may participate in the formation of functional invadopodia by 
docking Seprase (Fig. 5. Panel A and D ref [79]).  
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Seprase and DPPIV can form a complex localised at the invadopodia of fibroblasts on 
collagenous fibres that has both gelatinolytic and gelatin binding activities. This has 
been shown to facilitate cell migration [14, 18, 80, 81]. Seprase and DPPIV are highly 
homologous with both enzymes having the same domain structure (Fig. 1. ref [14]). 
Seprase shows 50% amino acid identity with DPPIV over the entire sequence, with 
almost 70% identity in the catalytic domain [12, 16, 21]. The Ser-Asp-His catalytic 
triad is conserved in both enzymes and their genes map to the same region of the 
human chromosome 2. Despite their shared structural features, Seprase and DPPIV 
differ in their tissue distribution and expression [65]. Seprase can form heteromeric 
complexes with DPPIV and the formation of the DPPIV-Seprase complex, which 
exhibits both prolyl peptidase activity and gelatinase activity, is necessary for cell 
migration on a collagen substrate [45]. It is possible that the two enzymes cooperate 
for efficient degradation of substrates and their consequent biological functions. The 
exact natures of the homodimer and heterodimer complexes of Seprase are poorly 
understood. 
 
A recent study has shown that Seprase-Urokinase-type plasminogen activator receptor 
(uPAR) membrane complexes are associated with the invadopodia of LOX cells, 
suggesting their co-operative roles in tumour invasion (Fig. 1. ref [78]). Urokinase 
plasminogen activator (uPA), a serine protease, converts the tissue zymogen 
plasminogen into plasmin. Plasmin has the ability to degrade most proteins in the 
ECM, including type IV collagen, laminin and fibronectin. In model systems, both the 
inhibition of uPA activity and the prevention of uPA binding to its receptor have been 
shown to limit the formation of metastasis [4]. Thus, Seprase may also be a potential 
candidate for anti-metastatic therapies. The interaction of uPA and the integrins have 
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been shown to regulate both adhesive and signalling activities of integrins [79]. The 
formation of the Seprase-uPAR membrane complexes is dependent upon both the 
cytoskeleton and integrins, specifically the β1 integrin [78].  
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6.4. Antiplasmin Cleaving Enzyme (APCE) 
As mentioned in Section 3, Lee and co-workers [82] have recently identified the 
soluble form of Antiplasmin Cleaving Enzyme (APCE) as Seprase. α2-Antiplasmin 
(AP) is a plasma glycoprotein of the Serpin (serine protease inhibitor) superfamily 
and is the primary physiological inhibitor of plasmin, a key enzyme in fibrin 
degradation [83]. The fibrinolytic system leads to the generation of plasmin from 
plasminogen through the action of Tissue or Urokinase Plasminogen Activator (t-PA 
or uPA). Studies into α2-antiplasmin have shown that it is present in the blood in a 
larger ‘pro’-form, α2APPRO and in a smaller mature form of α2APACT.  α2APPRO has 
464 amino acid residues, with Methionine at the N-terminus. The mature form 
α2APACT, has 452 amino acid residues, with Asparagine at its N-terminal [84, 85]. 
Both forms have been shown to be present in the blood (66% α2APACT ; 34% 
α2APPRO) and they both form a stable complex with plasmin. However the ‘pro’-form 
has remarkably less capacity of cross-linking fibrin (Fig. 5.) [86]. When α2APACT is 
cross-linked to fibrin (during clot formation), it retains the ability to effectively inhibit 
plasmin and protect fibrin from proteolysis. The processing of α2APPRO to α2APACT 
was shown to involve a plasma protease that cleaved the Pro12-Asn13 bond of the 
α2APPRO protein [82]. This protease is called Antiplasmin Cleaving Enzyme (APCE).  
 
APCE has been purified from human plasma using an initial ammonium sulphate 
fractionation, followed by hydrophobic, anion exchange, T-gel thiophilic, and 
immunoaffinity chromatographies [85]. The fact that APCE is found in human plasma 
and cleaves α2APPRO suggests that one of its physiologic functions is the regulation of 
α2APACT availability for plasmin inhibition within cross-linked fibrin [85]. Plasmin is 
resistant to α2-antiplasmin inhibition when it is associated with the plasma membrane 
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[87]. A study analysing the regulation of liver regeneration by the plasmin/α2-AP 
system suggests that this system plays an important role in the hepatic repair via 
proteolysis of the matrix elements and the clearance of cellular debris from the injured 
site [88]. Altered fibrin turnover may be responsible for tumour-promoting effects in 
several ways [89]. In clinical situations where fibrin formation is likely, the 
development of an agent that inhibits APCE might result in decreased amount of 
α2APACT available for cross-linking to fibrin as thrombi develop or as inflammation 
progresses. Abnormalities of haemostasis during tumour growth and metastasis have 
been observed and it has been shown that the ECM of neoplastic tissue is abnormally 
rich in fibrin bundles and is mixed with other stromal components [87]. Degradation 
of fibrin, fibrinogen and the ECM proteins by plasmin, in addition to the concomitant 
activation of the Urokinase Receptor by Urokinase Plasminogen Activator, has been 
suggested to facilitate tumour cells invasion and metastasis [89]. It has also been 
shown that elevated plasma levels of cross-linked fibrinogen indicated cancer-related 
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7. Substrate Specificity 
Most peptidases, even those that lack specificity, are unable to hydrolyse peptide 
bonds formed by proline due to the unique structure of the imino-acid and the special 
constraints it exerts on the peptide backbone structure [90]. Proline residues appear 
near the amino terminus of many biologically active peptides and appears to protect 
the peptide against degradation [90]. Seprase is one of a small number of peptidases 
which are capable of hydrolysing the proline peptide bonds.  
 
The identification of key substrates recognised by Seprase may provide a better 
understanding of the physiological role and of the pathways that control the activation 
of stromal fibroblasts during tumourigenesis. Seprase has been shown to have two 
proteolytic activities. Firstly it is a gelatinase [3, 11, 12] and secondly an N-terminal 
post-prolyl amino peptidase that can cleave Ala-Pro-AFC [26, 36, 51, 91]. Both the 
gelatinase and dipeptidyl peptidase activities of Seprase are mediated by an active site 
serine624 [12, 23]. Table 2 illustrates the kinetic constants obtained in studies of 
dipeptide substrates. Most serine proteases have no absolute substrate specificity [30]. 
They can cleave peptide bonds with a variety of side chains adjacent to the scissile 
bond. The S1-P1 hydrogen bond is a very important factor in the proper substrate 
orientation and the transition state stabilisation. Proline residues do not possess main 
chain NH groups and therefore the architecture of the S1 binding site is evolved to be 
much more specific in Seprase [30]. 
 
Substrate specificity studies using zymography have shown that Seprase degrades 
gelatin and thermally denatured type I and type IV collagens but not laminin, 
fibronectin, fibrin or casein [3, 12]. The gelatinase activity distinguishes Seprase from 
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DPPIV, which does not have gelatinase activity [22, 23]. However, an earlier report 
by Bermpohl and co-workers [24] suggested that DPPIV does have gelatinase 
activity.  
 
However, given that neither gelatin nor denatured collagen is a component of the 
ECM, the actual effect of Seprase on its alleged ECM substrate, collagen, is important 
to clarify. A recent study by Christiansen [92] has attempted to do this by examining 
the potential proteolytic effects of both Seprase and APCE toward purified types I, III 
and IV Collagens as substrates. In addition to this the individual effect of 
Seprase/APCE in combination with selected metalloproteinases (MMPs) that also 
participate in ECM remodelling was explored. This study demonstrated that neither 
Seprase nor APCE cleaved Collagen I into smaller peptides. This was also seen using 
Collagen III as substrate. The study also indicated that Seprase/APCE did not act 
secondarily to MMP-9 in the digestion of type IV Collagen. This group concluded 
that Seprase works in synchrony with other proteinases to cleave partially degraded or 
denatured Collagen I and III as ECM is excavated, and that derivative peptides might 
function to regulate malignant cell growth and motility [92].  
 
7.1. Modifications of bioactive peptides 
The endopeptidase activity of Seprase may function to regulate bioactive peptides. 
Due to the presence of a soluble form of Seprase in serum, any peptide circulating in 
the blood carrying a proline residue in the penultimate N-terminal position is a 
potential candidate substrate for its biological enzymatic activity. A proline positioned 
near the end of a peptide produces a significant ‘kink’. The natural substrates of 
Seprase are unknown, although the serum form has been shown to cleave the Pro12-
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Asn13 bond of α2 antiplasmin (α2APPRO) producing the Asn-α2 antiplasmin (α2APACT) 
[85]. The cleaved protein binds fibrin more efficiently and slows clot lysis by plasmin 
more effectively than full-length α2 antiplasmin (α2APPRO). Based on the Seprase 
cleavage site in α2APPRO, the specificity of Seprase in the P4-P4’ positions were 
defined [93]. The study confirmed that Seprase requires a Proline in the P1 position 
and Glycine (or D-amino acids) at the P2 position (Fig. 6.) [25, 93]. Seprase has been 
shown to have a broader tolerance at the P4, P3, P1’, and P2’ positions. In the P3 
position, Seprase had a preference for Ala and Ser. Less activity was observed against 
charged and aromatic amino acid residues, suggesting a preference for small, 
uncharged amino acids at the P3 position. Seprase seems to have a broader specificity 
at the P4 position. Compared to the previous study mentioned above, it was found that 
Seprase has a preference for Phe or Met at the P1’ position and least tolerance of His 
or Glu [25, 93]. 
 
Seprase has been shown to have a preference for N-blocked peptide substrates. 
Studies have shown that Seprase cleaves formyl-, benzyloxycarbonyl- and biotinyl- 
blocked substrates, which DPPIV cleaved poorly [94]. The substrate preferences as 
defined by Edosada [94] were used to design a peptidyl-chloromethyl ketone (cmk) 
that inhibited Seprase but not DPPIV.  
 
A fluorescence resonance energy transfer (FRET) peptide (Table 2.) was developed 
that contained the APCE-sensitive Pro12-Asn13 bond within the Thr9-Gln16 sequence 
of Met-α2AP (α2APPRO) [85]. Kinetic data using the FRET peptide has shown Seprase 
to have high affinity and kinetic efficiency, indicating that residues in the P4-P4’ 
region contribute to the substrate specificity [82]. The kcat/Km value for cleavage of 
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the FRET peptide is ~8-fold higher than for Z-Gly-Pro-AMC and ~12-fold higher 
than for Ala-Pro-AFC (Table 2.) [85].  
 
Combined results from the Edosada [93] study also provided a composite α2AP-
derived peptide substrate for Seprase namely, Ala-Ser-Gly-Pro-Ser-Ser. Comparing 
the kinetic parameters for the parental (TSGP-NQ) and composite α2AP-derived 
peptide substrate (ASGP-SS) shows that the Km value for the cleavage of the 
composite substrate was 3.3 fold higher than the parental substrate (Km = 4.3µM and 
1.3µM respectively). However, a concomitant 3.4 fold increase in kcat was observed, 
yielding a nearly equivalent catalytic efficiency (kcat/Km ) for each peptide (kcat/Km = 
1.3 x 106 M-1s-1 and 1.2 x 106 M-1s-1 respectively). 
 
Ultimately, the identification of the natural substrates of Seprase and the functions of 
Seprase activated peptides remains an important area to be investigated. 
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8. Possible clinical significance of Seprase 
 
Invasion with or without metastatic spread of cancer to distant sites has already 
occurred in a significant number of patients by the time their disease is detected [95]. 
Significant improvement in a patient’s survival may be achieved by halting the 
invasion process and containing the metastatic spread and growth of the disease. This 
may be achieved in several possible ways; 
 
8.1. Direct inhibition of Seprase protease activity 
An appealing target is the inhibition of tumour growth promotion by Seprase protease 
activity. Seprase is inhibited by the serine protease inhibitors DFP (0.005mM), PMSF 
(1mM), AEBSF (5mM) and APSF (0.5mM) [11, 12, 16, 25]. The 170kDa protease 
was sensitive to other inhibitors, such as NEM and HgCl2, that bind the sulfhydryl 
group of amino acid residues of the proteases [11]. These inhibition studies suggest 
that Seprase contains a catalytically active serine residue.  
 
A series of dipeptide proline diphenyl phosphonates were designed against DPPIV 
and Seprase [96]. The most potent inhibitor for both enzymes was found to be Gly-
ProP(OPh)2, which exhibited overall second-order rate constants of inactivation of 
5.24 x 105 M-1min-1 and 1.06 x 104 M-1min-1 against DPPIV and Seprase respectively. 
In the case of Seprase, it was found that the nature of the P2 residue of the inhibitor 
had a less pronounced effect on the second order rate constants, in contrast to DPPIV. 
It was found for DPPIV that the second order rate constants varied by one order of 
magnitude between the most effective [Gly-ProP(Oh)2] and the least effective [Ala-
ProP(Oh)2] inhibitors. This group also found that Gly-ProP(Oh)2 and Tyr-ProP(Oh)2 
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exerted a considerable dose dependent anti-invasive effect on the LOX melanoma cell 
line, in vitro [96]. 
 
A recent study by Tran [97] explored the structure-activity relationship of various N-
acyl-Gly-, N-acyl-Sar- and N-blocked-boroProline derivatives against three prolyl 
peptidases, Seprase, DPPIV and POP. Several N-acyl-Gly- and N-blocked-boro 
compounds showed low nanomolar inhibitory activity against Seprase and POP and 
selectively against DPPIV. N-Acyl-Sar-boroPro analogs retained selectivity against 
DPPIV and potent POP inhibitory activity but displayed decreased Seprase inhibitory 
activity. These results provide a foundation for future studies aimed at developing 
selective inhibitors for Seprase and POP [97]. 
 
The inhibition of the catalytic activity of Seprase with anti-catalytic antibodies has 
been investigated. It was found that the tumour-promoting effects of Seprase 
expression were inhibited by the use of these antibodies [29, 45]. Cheng and co-
workers also observed the over-expression of Seprase, leading to increased 
tumourigenicity, compared to a mutated S624A Seprase [91]. In this same study, 
Seprase activity was shown to be inhibited by Val-boroPro (PT-100, called 
Talabostat), a boronic acid inhibitor, with an IC50 of 4 x 10-8mol/L [91]. However, this 
inhibitor was also found to inhibit DPP IV , DPP-7, -8 and -9 [94, 98]. A further study 
has demonstrated that PT-100 could be used as an anti-cancer agent with a unique 
mechanism of action [99]. PT-100 has the potential to complement chemotherapy. 
Combination treatment using Taxol or Cisplatin resulted in significantly greater 
tumour inhibition and also rejection in 10% and 50% of mice respectively [100]. 
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N-acyl-Gly-Pro dipeptides were identified as Seprase selective substrate motifs and a 
second boronic acid inhibitor was designed, Ac-Gly-BoroPro [94]. It inhibited these 
prolyl peptidases with Ki values ranging from ~9- to 5400-fold higher than that for 
Seprase inhibition (Ki = 23nM for Seprase) [94]. This indicated that the Ac-Gly-Pro 
motif conferred significant Seprase selectivity and suggests that this could possibly be 
used to test Seprase as a therapeutic target. 
 
These studies together suggest that Seprase activity plays an important role in the 
promotion of tumour growth and that the Seprase protease is a good potential target 
for therapies designed to slow tumour growth.  
 
8.2. Seprase – a specific target for anti-tumour agents 
Surface expressed Seprase represents an additional potential target for 
immunolocalisation and immunotherapy of epithelial cancers. Since a large 
proportion of carcinomas contain an abundance of Seprase positive stroma, it is 
possible that they would be accessible to circulating mAb. Several groups have 
developed antibodies directed against Seprase. Antibodies were developed using the 
Seprase specific mAbF19 as a model and humanising the antibody [101-105].  
 
A phase I study investigated the effects of the mAbF19 targeted against metastatic 
colon cancer [65]. This study concluded that there were no toxic effects associated 
with intravenous administration of iodine131 labelled mAbF19 (131I-mAbF19). 
Increased expression of Seprase in primary and metastatic colorectal carcinomas with 
limited expression in normal adult tissue was also observed during this study. This 
highly selective expression pattern allowed for imaging of carcinoma lesions as small 
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as 1 cm in diameter. A logical concern with regards to the development of stromal 
targeting for cancer therapy is the notion that the stromal response to cancer (at the 
cellular and molecular level [65]) is similar to that of wound healing and Seprase is 
known to be expressed in healing dermal incisions [46]. However, the patients 
involved in this study would have had extensive scarring due to surgery but did not 
show any localisation of 131I-mAbF19 at these sites. Another phase I trial and limited 
phase II trial have been conducted with an unconjugated, humanized version of 
monoclonal antibody F19 to Seprase called sibrotuzumab [105, 106]. Results from 
this trial found that sibrotuzumab was well tolerated and relatively safe and a 
pharmacokinetic model has been developed for it [107]. Similar to the results obtained 
in the previous phase I trial [65], trace labelling with 131I and detection imaging 
revealed that sibrotuzumab specifically accumulated in the tumours and not in the 
normal tissues [101]. These studies suggest that mAbF19 has potential diagnostic and 
therapeutic applications and could be constructed to provide novel immune and non-
immune effector functions [65, 77].  
 
8.3. Disruption of Seprase signalling 
The targeting of antigens selectively expressed on the surface of tumour stromal 
fibroblasts or tumour capillary endothelial cells is currently being explored for the 
immunotherapeutic treatment of cancer [103, 108, 109]. By targeting or preventing 
the generation of tumour stroma or angiogenic blood vessels, tumour lesions may be 
deprived of the essential support services or nutrients required for survival and growth 
[110]. For reasons discussed in Section 8.2, Seprase is an important antigen for 
targeted therapy of the tumour stroma. [5] 
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Garin-Chesa and co-workers [7] propose that radiolabelled or toxin-conjugated mAbs 
or inflammatory mAb isotypes detecting Seprase may be used to induce cell damage 
in the Seprase positive supporting tumour stroma. This would lead to tumour cell 
necrosis (death) and inflammatory cell infiltrates. Recruitment of additional Seprase 
positive reactive fibroblasts would renew the target cell population and aid formation 
of fibrous capsules enclosing and isolating epithelial tumour cells. 
 
Studies in murine models have shown that immunologic targeting of the tumour 
vasculature, a key element of tumour stroma, can lead to protective immunity in the 
absence of significant pathology [109]. Targeting the tumour stroma, instead of 
tumour cells, reduces the incidence of immune evasion. Genetically more stable cells 
in the tumour stroma may prove to be a promising cellular target for cancer 
immunotherapy. Recent findings suggest that the tumour-stromal antigen Seprase can 
serve as a novel target for active vaccination against cancer, especially if combined 
with chemotherapy [111]. Tumour associated fibroblasts are also the primary source 
of Collagen type I, which has been shown to contribute to decreased chemotherapy 
drug uptake in tumours and play significant role in regulating tumour sensitivity to a 
variety chemotherapies [111]. In this study Loeffler and co-workers constructed an 
oral DNA vaccine which targets Seprase. This vaccine successfully suppressed 
primary tumour cell growth, metastasis of multi-drug resistant murine colon and 
breast carcinoma. Furthermore, tumour tissue of Seprase-vaccinated mice revealed 
markedly decreased Collagen type I expression and up to 70% greater uptake of 
chemotherapeutic drugs. Most importantly, Seprase vaccinated mice treated with 
chemotherapy showed a 3-fold prolongation in lifespan and marked suppression of 
tumour growth, with 50% of the animals completely rejecting a tumour cell challenge. 
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An important note from this article is that the DNA vaccine did not impair wound 
healing or damage normal tissue [111]. These are important factors if considering a 
Seprase vaccine as a potential immunotherapy.  
 
9. Conclusion 
In conclusion, since the discovery of Seprase in 1986 [7, 9], a lot of research has been 
performed on the localisation and expression of this protease. However, more research 
is needed on the biochemical and functional properties of this peptidase. Despite the 
numerous reports with suggestions on possible functions of the enzyme, the 
physiological role of Seprase has not been elucidated. Seprase does seem to have an 
important role in malignant cell invasion and metastasis by degrading the ECM, albeit 
working in synchrony with MMPs. Seprase may be involved in the development of 
over 90% of epithelial cancers and it has a potential as a predictive marker for the 
disease. The availability of a potent and selective, in vitro and in vivo applicable 
Seprase-inhibitor opens new perspectives for further studies of the physiological 
function of Seprase. Seprase regulation might be operative at different levels; genetic, 
post translational, hormonal and kinetic, but the mechanisms involved and the relative 
importance of these putative regulation strategies are not known. Further studies in 
this area would provide vital information on Seprase regulation and possibly elucidate 
a physiological role for the protease. This would ultimately tell us a lot more about the 
potential for Seprase to be used as a target for selective anticancer therapies. 
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Fig. 1. Summary of Intracellular Signalling 
Signalling from the normal epithelial cells to the stroma and back (black thin arrows) 
maintains the integrity of the epithelial tissue (thick arrow). During epithelial 
carcinogenesis, the signalling changes (dotted blue arrow) and this causes cancer-
associated changes in the stroma. The new cross-talk (dotted black arrows) between the 
cancer cells and the stroma leads to invasion (thick arrow). Adapted from De Wever and 
Mareel [112], and used with permission.  
 
(In Colour in print and on web) 
 
Fig. 2. Three-Dimensional Structure of Seprase 
The ribbon diagram illustrates the dimeric structure of Seprase (pdb accession code 
1Z68). The extracellular domain consists of 2 domains, an eight bladed β-propeller 
domain (indicated in blue) and an α/β hydrolase domain (indicated in green) that contains 
the catalytic triad. The catalytic residues are shown, catalytic Serine 624 (purple), 
Aspartic Acid 702 (cyan) and Histidine 734 (yellow). Generated using DeepView [113]. 
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Fig. 3. Three dimensional Seprase Domains 
(A) The ribbon diagram illustrates the α/β hydrolase domain (residues 27-53 and 493-
760) of Seprase (pdb accession code 1Z68). The α/β hydrolase domain contains the 
catalytic triad. The catalytic residues are shown, catalytic Serine 624 (pink), Aspartic 
Acid 702 (cyan) and Histidine 734 (yellow). α-helices are indicated in red, β-sheets are 
indicated in blue and the hydrogen bonds are indicated in green. (B) The ribbon diagram 
illustrates the eight bladed β-propeller domain (residues 54-492) of Seprase (pdb 
accession code 1Z68). Generated using DeepView [113]. 
 
(In Colour in print and on the web) 
 
Fig. 4. Amino acid sequence alignment of eukaryotic Seprase C-terminal  
Alignment of amino acid sequences for the C-terminal of Seprase; deduced sequences 
Homo sapiens (AAC51668), Mus musculus (AAH19190), Xenopus laevis (AAC59872) 
and the putative sequence Bos Taurus (XP_603457). Alignment was performed using 
MultAlin [114] and edited using GeneDoc [115]. Sequence similarity is represented by 
grey scaling, with black being the highest similarity. The amino acids of the catalytic 
triad (Ser624, Asp702, His734) are indicated (*). The serine protease consensus motif G-X-
S-X-G is underlined. 
 
(In Black and White in both print and on web) 
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Fig. 5. Summary of Fibrinolytic System 
Plasmin is generated from plasminogen through the action of Tissue or Urokinase 
Plasminogen Activator (t-PA or uPA). Plasmin digests Fibrin giving rise to degradation 
products. α2APPRO is processed to α2APACT by the action of APCE. α2APACT can cross-
link with both Plasmin and Fibrin. During clot formation, α2APACT becomes cross-linked 
to fibrin, where it retains the ability to effectively inhibit plasmin and protect fibrin from 
proteolysis.  
 
(In Black and white in both print and on web) 
 
 
Fig. 6. Seprase binding model 
The model shows a peptide with the P3-P1’ sequence Ser-D-Ala-Pro-Ile bound to Seprase. 
The surface depicts the structure of Seprase (pdb accession code 1Z68) with carbon 
atoms shown in white, oxygens in red, and nitrogens in blue. The carbon atoms of the 
peptide are in yellow and the side chain of the P2 D-Ala residue is highlighted in cyan. 
This figure is taken from ref [92] and used with permission. 
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